Fibrinolytic therapy for refractory COVID‐19 acute respiratory distress syndrome: Scientific rationale and review

Abstract The coronavirus disease 2019 (COVID‐19) pandemic has caused respiratory failure and associated mortality in numbers that have overwhelmed global health systems. Thrombotic coagulopathy is present in nearly three quarters of patients with COVID‐19 admitted to the intensive care unit, and bot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Christopher D. Barrett, Hunter B. Moore, Ernest E. Moore, Robert C. McIntyre, Peter K. Moore, John Burke, Fei Hua, Joshua Apgar, Daniel S. Talmor, Angela Sauaia, Deborah R. Liptzin, Livia A. Veress, Michael B. Yaffe
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley 2020-05-01
Colecção:Research and Practice in Thrombosis and Haemostasis
Assuntos:
acute respiratory distress syndrome
COVID‐19
fibrinolysis
pulmonary failure
tissue plasminogen activator
Acesso em linha:https://doi.org/10.1002/rth2.12357
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados